ATE289196T1 - Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen - Google Patents

Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen

Info

Publication number
ATE289196T1
ATE289196T1 AT00993165T AT00993165T ATE289196T1 AT E289196 T1 ATE289196 T1 AT E289196T1 AT 00993165 T AT00993165 T AT 00993165T AT 00993165 T AT00993165 T AT 00993165T AT E289196 T1 ATE289196 T1 AT E289196T1
Authority
AT
Austria
Prior art keywords
bacterial diseases
transdermal treatment
pleuromutilin derivatives
pleuromutilin
derivatives
Prior art date
Application number
AT00993165T
Other languages
English (en)
Inventor
Paul Howard Ripley
Erich Zeisl
Stefan Horkovics-Kovats
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8239432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE289196(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE289196T1 publication Critical patent/ATE289196T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00993165T 1999-11-22 2000-11-20 Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen ATE289196T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99123095 1999-11-22
PCT/EP2000/011519 WO2001037828A1 (en) 1999-11-22 2000-11-20 Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases

Publications (1)

Publication Number Publication Date
ATE289196T1 true ATE289196T1 (de) 2005-03-15

Family

ID=8239432

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00993165T ATE289196T1 (de) 1999-11-22 2000-11-20 Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen

Country Status (22)

Country Link
US (1) US6852756B1 (de)
EP (1) EP1231915B1 (de)
JP (1) JP3892298B2 (de)
KR (1) KR100529660B1 (de)
CN (1) CN100344281C (de)
AR (1) AR026523A1 (de)
AT (1) ATE289196T1 (de)
AU (1) AU764451B2 (de)
BR (1) BR0015722A (de)
CA (1) CA2386685C (de)
CO (1) CO5261531A1 (de)
DE (1) DE60018200T2 (de)
DK (1) DK1231915T3 (de)
ES (1) ES2237495T3 (de)
HK (1) HK1052643B (de)
MX (1) MXPA02005149A (de)
NZ (1) NZ518348A (de)
PT (1) PT1231915E (de)
RU (1) RU2264812C2 (de)
TW (1) TWI260220B (de)
WO (1) WO2001037828A1 (de)
ZA (1) ZA200203901B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102352A1 (en) * 2001-06-15 2002-12-27 Forty Eight Shelf (80) Limited Composition for the treatment of diseases which affect animals' hooves
CO5390081A1 (es) 2001-11-28 2004-04-30 Novartis Ag Compuestos organicos
ATE450535T1 (de) 2003-09-03 2009-12-15 Glaxo Group Ltd Neues verfahren zur herstellung von pleuromutilinderivaten
GB0504314D0 (en) 2005-03-02 2005-04-06 Glaxo Group Ltd Novel polymorph
EP1808431A1 (de) * 2006-01-16 2007-07-18 Nabriva Therapeutics Forschungs GmbH Mutilin Derivate und ihre Verwendung als Arzneimittel
CN102415989A (zh) * 2011-09-30 2012-04-18 上海恒丰强动物药业有限公司 盐酸沃尼妙林溶液剂及其制备方法
CN110225746A (zh) * 2016-11-09 2019-09-10 普罗维塔欧洲技术有限公司 用于治疗兽蹄感染的抗微生物制剂
GB201715122D0 (en) * 2017-09-19 2017-11-01 Omnipharm Dev Ltd Topical anti-infective formulation
KR102098289B1 (ko) * 2018-04-11 2020-04-07 경북대학교 산학협력단 발네물린을 유효성분으로 함유하는 골 질환 예방 또는 치료용 조성물
CN109431980A (zh) * 2018-12-27 2019-03-08 山东齐发药业有限公司 一种用于治疗动物皮肤细菌感染的羟啶妙林软膏剂及其制备方法
CN114366732B (zh) * 2022-02-23 2023-08-18 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 泰妙菌素在制备用于治疗银屑病的药物中的应用
CN117223712B (zh) * 2023-09-19 2024-08-02 贵州大学 一种截短侧耳素可湿性粉剂及其制备方法
CN117281117B (zh) * 2023-09-19 2024-08-30 贵州大学 一种截短侧耳素悬浮剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT301752B (de) * 1969-07-21 1972-09-25 Biochemie Gmbh Verfahren zur Herstellung neuer Pleuromutilin-Derivate
DE2614841A1 (de) 1976-04-06 1977-10-20 Bayer Ag Neue pour-on-formulierungen von anthelmintika
DE3560511D1 (en) * 1984-02-17 1987-10-01 Sandoz Ag Pleuromutilin derivatives, process for their preparation and their use
RU2025110C1 (ru) * 1991-06-03 1994-12-30 Сергей Владимирович Дайковский Способ лечения гнойно-некротических заболеваний конечностей животных
AT400674B (de) * 1991-07-24 1996-02-26 Biochemie Gmbh Pharmazeutische pleuromutilin-zubereitung
CZ212498A3 (cs) * 1996-01-03 1998-12-16 Smithkline Beecham P. L. C. Karbamoyloxyderiváty mutilinu, způsob výroby a farmaceutický prosředek
GB9614017D0 (en) 1996-07-04 1996-09-04 Biochemie Gmbh Organic compounds
GB9807503D0 (en) * 1998-04-07 1998-06-10 Smithkline Beecham Plc Use

Also Published As

Publication number Publication date
KR100529660B1 (ko) 2005-11-21
ZA200203901B (en) 2003-09-23
DE60018200D1 (de) 2005-03-24
BR0015722A (pt) 2002-07-23
AU2836501A (en) 2001-06-04
WO2001037828A1 (en) 2001-05-31
DE60018200T2 (de) 2006-01-12
CA2386685A1 (en) 2001-05-31
KR20020053876A (ko) 2002-07-05
CN100344281C (zh) 2007-10-24
US6852756B1 (en) 2005-02-08
CO5261531A1 (es) 2003-03-31
EP1231915B1 (de) 2005-02-16
ES2237495T3 (es) 2005-08-01
AR026523A1 (es) 2003-02-12
DK1231915T3 (da) 2005-05-02
JP3892298B2 (ja) 2007-03-14
MXPA02005149A (es) 2002-11-07
TWI260220B (en) 2006-08-21
CN1391472A (zh) 2003-01-15
RU2002116252A (ru) 2004-01-20
HK1052643B (zh) 2008-03-14
NZ518348A (en) 2003-11-28
PT1231915E (pt) 2005-07-29
EP1231915A1 (de) 2002-08-21
JP2003514856A (ja) 2003-04-22
AU764451B2 (en) 2003-08-21
RU2264812C2 (ru) 2005-11-27
CA2386685C (en) 2009-05-19
HK1052643A1 (zh) 2003-09-26

Similar Documents

Publication Publication Date Title
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE60022916D1 (de) Reboxetin zur Behandlung von peripheren Neuropathien
ATE524173T1 (de) Verwendung von (-)(3-trihalomethylphenoxy)(4- halophenyl)essigsäurederivaten zur behandlung von hyperurikämie
DE60319865D1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
DE60031710D1 (de) Fettsäurederivat zur behandlung von externen sekretionsstörungen
DE60029033D1 (de) Verfahren zur Behandlung von Tissuepapier
DE60022826D1 (de) Absorbierender Wegwerfartikel zur Behandlung von Fäkalien
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE60017174D1 (de) Rivastigmine zur behandlung von augenerkrankungen
DE60023555D1 (de) Verfahren zur behandlung von gewebe
ATE251167T1 (de) Oxazinocarbazole zur behandlung von cns- erkrankungen
DE60043648D1 (de) Medikamente zur behandlung von periodontalen erkrankungen
ATE261965T1 (de) Bispidin-derivate zur behandlung von herzarrhythmien
ATE226440T1 (de) Zusammensetzung zur behandlung von psoriasis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1231915

Country of ref document: EP